The School of Pharmacy Henry A. Palmer CE Finale, named for beloved professor and mentor, Dr. Henry A. Palmer, is a continuing education program offered at the end of each calendar year. Held during December, the program helps pharmacists fulfill their last minute CE requirements. The program is typically not a single theme, but an ala carte program offering a variety of presentations covering contemporary issues in pharmacy practice/therapeutics. Pharmacists may enroll in one or more [up to 8] hours of continuing education.
Henry A. Palmer CE Finale 2023
LIVE and IN PERSON!
Friday, December 15, 2023
Sheraton Hartford South
Rocky Hill, CT
7:30 am-5:00 pm
For a full course description see the Henry A. Palmer Brochure
Download Handouts for CE Finale-coming in December
LAW: Off-Label Drug Use and The Pharmacist’s Role – 2 slides per page
LAW: Off-Label Drug Use and The Pharmacist’s Role – 6 slides per page
The ABCD of Off-Label Medications for Weight Management – 2 slides per page
The ABCD of Off-Label Medications for Weight Management – 6 slides per page
TOP 10 Cardiovascular Drugs Used Off Label!!! – 2 slides per page
TOP 10 Cardiovascular Drugs Used Off Label!!!-6 slides per page
Indication Deviation in Women’s Health: Off-Label Drug Use from Conception to Menopause-2 per page
Indication Deviation in Women’s Health: Off-Label Drug Use from Conception to Menopause-6 slides per page
Law: Braving Buprenorphine (BUP): Exploring Off Label Use of Products for Pain Management and Opioid Use Disorder (OUD) – 2 slides per page
Law: Braving Buprenorphine (BUP): Exploring Off Label Use of Products for Pain Management and Opioid Use Disorder (OUD) – 6 slides per page
Immunization: It is Now Time to Make it Unclear: Reconciling Differences between Public Health Vaccine Recommendations and FDA Product Labeling – 2 slides per page
Immunization: It is Now Time to Make it Unclear: Reconciling Differences between Public Health Vaccine Recommendations and FDA Product Labeling – 6 slides per page
Antipsychotic Utilization in a Pediatric Population – 2 slides per page
Antipsychotic Utilization in a Pediatric Population – 6 slides per page
Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control – 2 slides per page
Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control – 6 slides per page
CE FINALE SCHEDULE/TOPICS/LEARNING OBJECTIVES
7:30-8:00 a.m. – Registration and Check-In/Sign-In
8:00-8:10 a.m. – Opening Remarks- Jeannette Wick
8:10-9:10 a.m. – LAW: Off-Label Drug Use and The Pharmacist’s Role
Jennifer A. Osowiecki, RPh, JD, Cox & Osowiecki, LLC, Hartford, CT
| At the conclusion of this presentation, pharmacists will be able to: |
| 1. Define the term “off-label” in terms of drug promotion, prescribing, and use.
2. Distinguish between the use of unapproved drugs and unapproved uses of approved drugs. 3. List at least two reasons why off-label drug promotion could be harmful to patients. 4. Explain whether a pharmacist has an obligation to dispense (or not dispense) a drug prescribed for an off-label use. 5. Identify potential liabilities for pharmacists who recommend off-label use of a drug. |
0009-0000-23-037-L03-P (0.1 CEU or 1 contact hour) (application-based)
9:15-10:15 a.m. – The ABCD of Off-Label Medications for Weight Management
Devra Dang, PharmD, CDCES, FNAP, Associate Clinical Professor, UConn School of Pharmacy, Storrs, CT
| At the conclusion of this presentation, pharmacists will be able to: |
| 1. Discuss the main principles of management of adiposity-based chronic disease (ABCD)
2. Identify the efficacy of commonly prescribed medications that may be used off-label for weight reduction 3. List major safety considerations for medications prescribed off-label for weight reduction |
0009-0000-23-038-L01-P (0.1 CEU or 1 contact hour) (Knowledge-based
10:20-11:20 a.m. TOP 10 Cardiovascular Drugs Used Off Label!!!
Michael White, PharmD, FCCP, FCP, BOT Distinguished Professor and Chair of Pharmacy Practice University of Connecticut School of Pharmacy, Storrs, CT
| At the conclusion of this presentation, pharmacists will be able to: |
| 1. Identify how an FDA approved and off label indication differ and the implications of that differential designation
2. Identify which 10 FDA approved cardiovascular drugs have the most promising off label uses for treating other cardiac or noncardiac disorders 3. Describe the mechanisms of action for the purported off label uses of these drugs 4. Identify which national guidelines or consensus statements recommend the off-label use of drugs |
0009-0000-23-039-L01-P (0.1 CEU or 1 contact hour) (Application-based)
11:25-12:25 p.m. – Indication Deviation in Women’s Health: Off-Label Drug Use from Conception to Menopause
Kelsey Giara, PharmD, Freelance Medical Writer, Pelham, NH
| At the conclusion of this presentation, pharmacists will be able to: |
| 1. Recognize diverse instances of off-label drug use in women’s health, spanning pre-conception to menopause
2. Discuss risks and advantages associated with off-label drug utilization during various reproductive stages 3. Identify the pharmacist’s role in advocating for safe and informed off-label drug use for women’s health |
0009-0000-23-040-L01-P (0.1 CEU or 1 contact hour (Application-based)
12:25-12:45 p.m. – BREAK-light snacks will be served.
12:45-1:45 p.m. –Law: Braving Buprenorphine (BUP): Exploring Off Label Use of Products for Pain Management and Opioid Use Disorder (OUD)
Megan Mitchell, PharmD, MS, Clinical Pharmacy Specialist in Palliative Care and Pain Management, University of Kentucky Healthcare, Lexington, KY
| At the conclusion of this presentation, pharmacists will be able to: |
| 1. Review the unique pharmacology of buprenorphine (BUP) including opioid receptor activity and binding affinity
2. Differentiate between the FDA approved buprenorphine products and their indications 3. Identify a comprehensive plan for safe and efficacious use of buprenorphine products for pain and opioid use disorder (OUD) 4. Recognize utility of prescribing off label use of buprenorphine products and legislature changes that supports such practice |
0009-0000-23-041-L03-P (0.1 CEU or 1 contact hour) (Application-based)
1:50-2:50 p.m. – Immunization: It is Now Time to Make it Unclear: Reconciling Differences between Public Health Vaccine Recommendations and FDA Product Labeling
Jeffery Aeschlimann, PharmD, Associate Clinical Professor-Infectious Disease Specialty, University of Connecticut School of Pharmacy, Storrs, CT
| At the conclusion of this presentation, pharmacists will be able to: |
| 1. Compare and contrast the roles & activities of the Center for Biologics Evaluations and Research (CBER), US Food & Drug Administration (FDA), Centers for Disease Control & Prevention (CDC), and the Advisory Committee on Immunization Practices (ACIP) during the development and clinical use of vaccines in the United States.
2. Describe one specific example where the routine clinical use of a vaccine may differ from FDA-approved product prescribing information due to the following: (a) costs (b) disease epidemiology (c) public acceptance (d) vaccine supplies
|
0009-0000-23-042-L06-P (0.1 CEU or 1 contact hour) (Application-based)
2:55-3:55 p.m. – Antipsychotic Utilization in a Pediatric Population
Megan Ehret, PharmD, MS, BCPP, Professor, Co-Director of Mental Health Program , University of Maryland School of Pharmacy, Baltimore, MD
| At the conclusion of this presentation, pharmacists will be able to: |
| 1. Describe current practice guidelines the use of antipsychotic medications in a pediatric population.
2. Outline adverse effects associated with the use of antipsychotic medication in a pediatric population. 3. Determine when to initiate an antipsychotic medication in a pediatric patient. |
0009-0000-23-043-L01-P (0.1 CEU or 1 contact hour) (Knowledge-based)
4:00-5:00 p.m. – Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control
Jeannette Y. Wick, RPh, MBA, Director Office of Professional Pharmacy Development, UConn School of Pharmacy, Storrs, CT
| At the conclusion of this presentation, pharmacists will be able to: |
| 1. LIST the numerous off label uses of gabapentin and trazodone.
2. DESCRIBE which of those uses are supported by actual evidence 3. INDICATE the potential adverse effects and medication related problems that patients who take these drugs may experience 4. ARTICULATE ways to approach prescribers with alternative suggestions |
0009-0000-23-044-L05-P (0.1 CEU or 1 contact hour) (Knowledge-based)
CE FINALE ENCORE WEBINARS AVAILABLE
If you find you cannot make it to our LIVE EVENT on Friday, December 15th, you can participate in our 7 ENCORE LIVE WEBINARS that will be streamed on the following dates:
- Monday, December 18, 12:00 (Noon) – 1:00 pm – TOP 10 Cardiovascular Drugs Used Off Label!!!
- Monday, December 18, 7:00 pm – 8:00 pm – Indication Deviation in Women’s Health: Off-Label Drug Use from Conception to Menopause
- Tuesday, December 19, 12:00 (Noon) – 1:00 pm – Immunization: It is Now Time to Make it Unclear: Reconciling Differences between Public Health Vaccine Recommendations and FDA Product Labeling
- Tuesday, December 19, 7:00 pm-8:00 pm – Antipsychotic Utilization in a Pediatric Population
- Tuesday, December 19, 8:10-9:10 – The ABCD of Off-Label Medications for Weight Management
- Wednesday, December 20, 12:00 pm-1:00 pm – Law: LAW: Off-Label Drug Use and The Pharmacist’s Role
- Wednesday, December 20, 7:00 pm – 8:00 pm – Patient Safety: Gabapentin and Trazadone: Off-labels Use is Out of Control
The University of Connecticut, School of Pharmacy, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Statements of Credit will be awarded at CE Finale based on full sessions attended and completed online evaluations. Pharmacists can earn up to 8 contact hours (0.80 CEU) two of which are law credits, and one is an Immunization Credit and one is a Patient Safety Credit.
Please Note: Pharmacists who wish to receive credit for the presentations MUST ACCURATELY complete the registration and online evaluations within 45 days of the live program (January 31, 2024). Participants are accountable for their own continuing education requirements for license renewal and are required to follow up with joanne.nault@uconn.edu to resolve a discrepancy in a timely manner. PLEASE CHECK YOUR CPE MONITOR PROFILE within 3 days of submission to assure that your credits have been properly uploaded. Requests for exceptions will be handled on a case-by-case basis and may result in denial of credit.
Activity Support: There is no funding for this program.